In vitro and in vivo models for testing arrhythmogenesis in drugs

Area of Science:

• Pharmacology
• Cardiology
• Toxicology

Background:

• Drug-induced QT interval prolongation and torsades de pointes (TdP) pose significant safety concerns.
• Early identification of proarrhythmic drug candidates is essential to protect public health.
• Predictive animal models are needed to balance drug development risks and benefits.

Purpose of the Study:

• To review the advantages and disadvantages of various in vivo and in vitro animal models.
• To assess the utility of these models in predicting drug-induced proarrhythmia liability.
• To inform strategies for early-stage drug safety evaluation.

Main Methods:

• Review of existing literature on animal models for proarrhythmia assessment.
• Discussion of in vivo (e.g., animal studies) and in vitro (e.g., cell-based assays) approaches.
• Comparative analysis of model relevance and predictivity.

Main Results:

• Various animal models exist for evaluating QT prolongation and TdP risk.
• Each model possesses unique strengths and limitations regarding clinical translatability.
• No single model perfectly predicts human cardiac risk.

Conclusions:

• Careful selection and validation of animal models are critical for drug safety assessment.
• Utilizing a combination of models may improve prediction of proarrhythmic potential.
• Optimized preclinical testing can mitigate risks associated with drug-induced cardiac events.